Incidence, significance, and subtypes of hemophilia BM in a large population of hemophilia B patients
- PMID: 7059689
- DOI: 10.1007/BF00320685
Incidence, significance, and subtypes of hemophilia BM in a large population of hemophilia B patients
Abstract
Eleven patients with hemophilia BM were found out of a population of 66 patients with hemophilia B. Factor IX activity in the hemophilia BM varied between less than 1% and 1.6% of normal but factor IX antigen was normal or only slightly reduced in each instance. Thrombotest clotting time was variably prolonged and was not corrected by the addition of normal plasma. Thrombotest mixing experiments and dilution curve studies confirmed the presence of the inhibitor in every patient. There are at least two forms of hemophilia BM, a severe one and a mild one. In the first form, Thrombotest is severely prolonged (90-120 s). In the other, the prolongation is mild or moderate (60-80 s). A positive correlation exists between the antigen-activity difference (delta antigen-activity) and the prolongation of Thrombotest both in the propositi and in obligatory carriers. The criteria for the diagnosis of hemophilia BM are the following: prolonged PTT, prolonged Thrombotest, lack of correction of Thrombotest by the addition of normal plasma while PTT is fully corrected. The lack of correction of Thrombotest in the presence of a full correction of PTT, is the unique clotting feature.
Similar articles
-
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.Vox Sang. 1977;32(4):230-8. doi: 10.1111/j.1423-0410.1977.tb00635.x. Vox Sang. 1977. PMID: 857424
-
Sensitive solid phase enzyme immunoassay for factor IX antigen and classification of hemophilia B.Haemostasis. 1983;13(1):9-16. doi: 10.1159/000214698. Haemostasis. 1983. PMID: 6341181
-
An immunological method for detection of the carrier of hemophilia B.Thromb Haemost. 1976 Nov 30;36(2):441-50. Thromb Haemost. 1976. PMID: 1036844
-
Inhibitor antibodies to factor VIII and factor IX: management.Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821. Semin Thromb Hemost. 2000. PMID: 10919411 Review.
-
Hemophilia and von Willebrand's disease: genetic considerations.Ann Clin Lab Sci. 1980 Mar-Apr;10(2):123-7. Ann Clin Lab Sci. 1980. PMID: 6770741 Review.
Cited by
-
Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.Clin Appl Thromb Hemost. 2018 May;24(4):560-565. doi: 10.1177/1076029617721012. Epub 2017 Aug 4. Clin Appl Thromb Hemost. 2018. PMID: 28774197 Free PMC article. Review.